Table 1.
Samples, conditions, and concentrations used for the assessment of methylation levels by means of LINE-1 and LUMA, of which the cell lines had been obtained previously [39]
| Data subset | Tissue (cell type) | Age (mean ± SD) (years) | n (total number of replicates) | Condition | Treatment duration | Concentrations |
|---|---|---|---|---|---|---|
| MCF7 | Human breast cancer cell line | – | 6 | Untreated | 3 days | – |
| 7 | DMSO | 3 days | 0.1 (%) | |||
| 9 | 5-Aza-CdR | 3 days | 0.1/0.3/1 (μM) | |||
| 7 | SAM | 3 days | 10/50/100 (μM) | |||
| 5 | DCP | 3 days | 0.1/1/10 (mg/l) | |||
| 11 | Methadone | 3 days | 1/10/25/50/75/100 (μM) | |||
| 6 | RG108 | 3 days | 10/50/70/100 (μM) | |||
| 4 | 5-Aza-CdR + SAM | 3 days | 0.3 + 50/100 (μM) | |||
| 2 | 5-Aza-CdR + DCP | 3 days | 0.3 (μM) + 10 (mg/l) | |||
| 9 | 5-Aza-CdR + Methadone | 3 days | 0.3 + 10/25/50/75/100 (μM) | |||
| 2 | 5-Aza-CdR + SAM + DCP | 3 days | 0.3 (μM) + 100 (μM) + 10 (mg/l) | |||
| 2 | RG108 + DCP | 3 days | 100 (μM) + 10 (mg/l) | |||
| 3 | SAM + DCP | 3 days | 100 (μM) + 10 (mg/l) | |||
| SHSY5Y | Human neuronal cell line | – | 7 | Untreated | 3 days/7 days | |
| 7 | DMSO | 3 days/7 days | 0.1 (%) | |||
| 12 | 5-Aza-CdR | 3 days/7 days | 0.1/0.3/0.5/1 (μM) | |||
| 1 | SAM | 3 days | 30 (μM) | |||
| 3 | Methadone | 3 days | 10/100 (μM) | |||
| 1 | 5-Aza-CdR + SAM | 3 days | 0.3 + 30 (μM) | |||
| 3 | 5-Aza-CdR + Methadone | 3 days | 0.3 + 10/100 (μM) | |||
| Human blood | Healthy subjects | 39.57 ± 7.02 | 83 | Untreated | – | |
| Pain patients, opioid treated | 47.83 ± 7.36 | 29 | Opioid analgesics | >1 year | 52.69 mg ± 22.11 OMEa | |
| Pain patients non-opioid treated | 45.68 ± 11.63 | 19 | Non-opioid analgesics |